INMB
INmune Bio Inc.
( )
vista's key points
- An exciting clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
- INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.
- INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.
- By controlling residual disease, INmune believes that patients may live longer.
- Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
vista's key points
- An exciting clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
- INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.
- INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.
- By controlling residual disease, INmune believes that patients may live longer.
- Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
company profile
vista's view
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction...
Read Moreexclusive content
Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.
vp watchlist
The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.
recent news
-
USPTO Issues Patent Covering Use of XPro™...
22 June 2022 | 12:00 pm
-
INmune Bio, Inc. Presents Data on Combination...
16 June 2022 | 12:00 pm
-
Mizner Park office space fills up
9 June 2022 | 11:35 am
Interviews
Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.
Get Free Email Updates